An inverse agonist of LRH-1 (IC50 = 3.7 μM) with maximum efficacy of 64% repression; inactive at the related SF1 transcriptional activator; alters the expression of haptoglobin, SAA1, and SAA4, induces the death of ER negative MDA-MB-231 breast cancer cells, and inhibits the StAR promoter (IC50 = 2.05 μM)